Capricor Therapeutics (CAPR) Current Deferred Revenue (2014 - 2026)

Capricor Therapeutics' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $12.0 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue changed 0.0% year-over-year to $12.0 million in Q1 2026; TTM through Mar 2026 was $12.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $12.0 million, changed 0.0% from the prior year.
• Current Deferred Revenue held at $12.0 million in Q1 2026 per CAPR's latest filing, from $12.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $40.0 million in Q1 2022 and bottomed at $12.0 million in Q4 2024.
• The 5-year median for Current Deferred Revenue is $15.7 million (2022), against an average of $19.0 million.
• Across the five-year window, Current Deferred Revenue jumped 86.16% in 2023 and slumped 50.56% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $18.0 million in 2022, then jumped by 34.98% to $24.3 million in 2023, then plunged by 50.56% to $12.0 million in 2024, then changed by 0.0% to $12.0 million in 2025, then changed by 0.0% to $12.0 million in 2026.
• Per Business Quant, the three latest CAPR Current Deferred Revenue figures stand at $12.0 million (Q1 2026), $12.0 million (Q4 2025), and $12.0 million (Q3 2025).